Antisperm Immunity for Contraception by Naz, R. K.
Faculty Scholarship
2006
Antisperm Immunity for Contraception
R. K. Naz
Follow this and additional works at: https://researchrepository.wvu.edu/faculty_publications
This Article is brought to you for free and open access by The Research Repository @ WVU. It has been accepted for inclusion in Faculty Scholarship
by an authorized administrator of The Research Repository @ WVU. For more information, please contact ian.harmon@mail.wvu.edu.
Digital Commons Citation
Naz, R. K., "Antisperm Immunity for Contraception" (2006). Faculty Scholarship. 58.
https://researchrepository.wvu.edu/faculty_publications/58
153
Journal of Andrology, Vol. 27, No. 2, March/April 2006
Copyright q American Society of Andrology
Andrology Lab Corner*Antisperm Immunity for
Contraception
RAJESH K. NAZ
From the Reproductive Immunology and Molecular
Biology Laboratories, Department of Obstetrics and
Gynecology, The West Virginia University, School of
Medicine, Morgantown, West Virginia.
Presently, there are only limited options available for fam-
ily planning. Contraceptive modalities available to wom-
en include hormonal contraceptives (birth control pills,
contraceptive patch, and hormone injections), natural
methods (abstinence near ovulation and early withdrawal
before ejaculation), intrauterine devices (IUDs; copper
IUD, vaginal rings, diaphragm, and spermicidal combi-
nations), and sterilization (Contraception online, 2004;
Upadhyay, 2004; Harper, 2005). The contraceptive op-
tions available to men are vasectomy, condoms, and early
withdrawal. Vasectomy is the most effective male contra-
ceptive method currently available. However, vasectomy
is a permanent procedure with a limited success rate of
fertility reversal even after successful surgical reanasto-
mosis (Silber and Grotjan, 2004). Therefore, for men who
wish to father a child at a later time, condoms and with-
drawal are the only contraceptive options. However, these
two methods are either not readily acceptable or have
high failure rates. Even with the available contraceptive
methods, the world population exceeds 6.48 billion and
will grow by 1 billion every 12 years at the present rate
of population explosion (Anonymous World POP Clock
Projection US Census Bureau, October 2005). In addition,
unintended pregnancies continue to impose a major public
health issue. In the United States alone, half the pregnan-
cies are unintended, which results in more than 1 million
elective abortions each year (Henshaw, 1998; Grow and
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Ahmed, 2000). In more than half of these unintended
pregnancies, the women were using some method of con-
traception. The 2004 Institute of Medicine report indicates
that between 1995 and 2000, more than one quarter of
1.2 billion pregnancies were unwanted (Institute of Med-
icine report, 2004). Thus, there is an urgent need for a
better method of contraception that is reversible, nonste-
roidal, nonbarrier, intercourse-independent, acceptable,
and effective. The most important properties of an ideal
contraceptive method desired by women are that it should
be highly effective and safe, is inexpensive, has a pro-
longed duration of action, is rapidly reversible and easily
accessible, requires infrequent administration, and can be
used privately (Contraception online, 2004). A contracep-
tive vaccine (CV) can fulfill most of the properties of an
ideal contraceptive. Since the developed nations and most
of the developing nations have an infrastructure for mass
immunization, the development of vaccines for contra-
ception is an exciting proposition.
Various targets have been explored for the development
of CVs. These broadly fall into three categories: vaccines
inhibiting gamete production (gonadotropin-releasing
hormone [GnRH], follicle-stimulating hormone [FSH],
and leuteinizing hormone [LH]), gamete function (zona
pellucida [ZP] proteins and sperm antigens), or gamete
outcome (human chorionic gonadotropin [hCG]; Naz,
2005a; Naz et al, 2005). Advantages of GnRH-based vac-
cines are that they are effective in several species and can
be used for both males and females. However, they affect
sex steroids, causing impotency, thus, are not acceptable
for human use. GnRH-based vaccines have been taken
over by pharmaceutical companies for fertility control in
domestic pets, farm animals, and wild animals, and for
noncontraceptive purposes, such as prostatic hypertrophy
and carcinoma (Ferro and Stimson, 1999; Simms et al,
2000). Advantages of FSH-based vaccines are that they
can inhibit spermatogenesis in males of several species
and can potentially provide a male contraceptive. How-
ever, FSH-based vaccines cause oligospermia rather than
azoospermia. This incomplete efficacy has hindered fur-
ther progress (Moudgal et al, 1997). The advantages of
LH- or LH receptor–based vaccines are that they are ef-
fective in both males and females (Thau et al, 1987; Sax-
ena et al, 2002). However, LH- or LH receptor–based
vaccines affect sex steroids; therefore, they are not ac-
ceptable for humans. Disadvantages of CVs targeting
gamete production are that they affect sex steroids and/
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or show only a partial effect in reducing fertility. Contra-
ceptive vaccines targeting gamete functions are better
choices. Vaccines based on ZP proteins are quite effica-
cious in producing contraceptive effects. However, they
induce oophoritis, affecting sex steroids (Tung et al, 1999;
Aitken, 2002). Vaccines based on ZP proteins have been
successfully used for controlling wild and zoo animals,
such as deer, horses, elephants, and dogs (Kirkpatrick and
Turner, 2002). Sperm antigens constitute a promising and
exciting target for CVs and, at the present time, no dis-
advantages are known. Vaccines targeting gamete out-
come primarily focus on the hCG molecule. The hCG-
based vaccines have undergone phase I and II clinical
trials in women, which demonstrated efficacy and lack of
immunopathology (Talwar et al, 1994). However, there
was a variable immune response observed among vacci-
nated women. The present article will focus on the de-
velopment of CVs based on sperm antigens.
Rationale for Sperm Vaccine Development
There is a strong rationale for the development of a
sperm-based vaccine. The sperm cell is immunogenic in
both males and females. Immunization of several species
of animals and humans with sperm/testis preparations de-
velop antisperm antibodies (ASA), leading to infertility
(Menge, 1970; Allardyce, 1984). The following data pro-
vides a strong rationale for the development of a sperm
CV for humans. In 1932, Baskin injected 20 fertile wom-
en, who had at least 1 previous pregnancy, with their hus-
band’s sperm (Baskin, 1932). These women developed
ASA and no conception was reported for up to 1 year of
observation. A US patent was issued for this spermatoxic
vaccine in 1937 (US patent 2103240). More than 70% of
men develop ASA after vasectomy (Liskin et al, 1983),
and there is a limited success in the regain of fertility,
even after successful surgical reanastomosis in vaso-
vasostomy attributed to the presence of ASA (Silber and
Grotjan, 2004). Up to 2% to 30% cases of infertility may
be associated with the presence of ASA in the male or
female partner of an infertile couple (Ohl and Naz, 1995).
These ASA are causative factors of infertility, because
disappearance of ASA cause regain of fertility (Bronson
et al, 1984). These findings provide evidence that sper-
matozoa can generate an immune response in both men
and women that can lead to a contraceptive state. How-
ever, the whole sperm cannot be used for the development
of CV. There are numerous antigens present on the sur-
face and internally in sperm that are shared with somatic
cells. Thus, immunization with the whole sperm can
cause immunopathological consequences in other tissues
and organs. The usefulness of a sperm antigen is contin-
gent on sperm-specific expression, surface expression ac-
cessible to antibody binding, and its role in fertilization/
fertility. In addition, the sperm antigen, alone or after con-
jugation with an appropriate carrier protein, should be
able to raise high titer and long-lasting antibody response
in circulation and locally in the genital tract. If the sperm
antigen is also involved in human immunoinfertility, then
it is an especially attractive candidate. An ideal sperm
antigen for immunocontraception should have tissue-
specific expression on sperm surface, be involved in
sperm-ZP binding, and be involved in human immunoin-
fertility.
Sperm Antigens
Various methodologies of genomics and proteomics have
been used to delineate sperm antigens that have a role in
fertilization/fertility and can be used for the CV devel-
opment. Recently, using gene knockout technology, at
least 93 novel testis/sperm genes/proteins have been iden-
tified that have a crucial role in various aspects of fertility
(Naz and Rajesh, 2005a; Naz and Rajesh, 2005b). Some
of these gene knockouts cause a defect in testis devel-
opment and endocrine milieu, some in spermatogenesis,
some in mating behavior, some in sperm structure/func-
tion/motility, and some in fertilization. The majority of
these knockouts also demonstrated an effect on nonrepro-
ductive organs concomitant with an effect on fertility. We
performed an extensive database analysis of these genes/
proteins to examine how many of these have the char-
acteristics required for the CV development, as discussed
above. The knockouts of only a few genes/proteins in-
duced a specific effect on fertility without a serious side
effect. Further analysis of these genes/proteins indicated
that majority are not expressed on the sperm surface, thus,
are not amenable to antibody binding. Although these
genes/proteins can provide ideal targets for pharmacolog-
ical inhibition for contraception, they are not suitable for
CV development. The gene knockout technology is a
powerful approach to identify suitable novel targets, and
the list of gene knockout mice is ever growing.
The molecules involved in sperm-oocyte membrane fu-
sion have been actively examined for some time. Various
candidates have been proposed, including DE, cluster of
differentiation (CD)46, equatorin Sperad, and sperm ac-
rosomal membrane-associated protein (SAMP)32 (Stein et
al, 2004). CD46 gene knockout mice do not show a de-
fective sperm-oocyte fusion (Inoue et al, 2003). A Dis-
integrin and Metalloprotease (ADAM) family proteins
have drawn a considerable attention because they have a
putative fusion peptide (ADAM1) and disintegrin domains
(ADAM2 and ADAM3; Nishimura et al, 2004). However,
ADAM1, ADAM2, and ADAM3 gene knockout mice did
not show a defect in sperm-oocyte membrane fusion, but
did show an impairment in sperm-zona binding (Cho et
al, 1998). CD9 present on the oocyte plasma membrane
seems to be essential for fusion with the sperm cell (Le
Naour et al, 2000). It was thought that integrins a6 and
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b1 present on sperm are involved in binding to oocyte
CD9 for sperm-oocyte fusion (Almeida et al, 1995). How-
ever, gene knockout of these molecules did not inhibit
fertility (He et al, 2003). Recently, a gene knockout was
reported that is very interesting. The gene knockout mice
of a sperm gene, designated as Izumo, are healthy, but all
males are sterile (Inoue et al, 2005). Izumo is named after
a Japanese shrine dedicated to marriage. The male mice
produce normal-appearing sperm that bind to and pene-
trate the ZP but are incapable of fusing with the oocyte
membrane. Human sperm also express Izumo protein.
Izumo protein is not detectable on ejaculated sperm but
becomes detectable after sperm cell undergoes acrosome
reaction. Izumo antigen seems to be an interesting mol-
ecule, and its usefulness in the CV development needs to
be investigated. Because it is not exposed until the sperm
cell undergoes acrosome reaction, the antibodies have to
be present at that particular time and space for binding to
Izumo antigen. It is not clear at the present time whether
the sperm-oocyte plasma membrane fusion event is a suit-
able target for immunocontraception (Naz et al, 2001).
Although several sperm genes/antigens have been de-
lineated, cloned, and sequenced; and antibodies to some
of these antigens affect sperm function/fertilization in vi-
tro, only immunization with a few of them cause a con-
traceptive effect in vivo in any animal model. Notable
among these are lactate dehydrogenase-C4 (LDH-C4;
Goldberg and Herr, 1999), PH-20 (Primakoff et al, 1988),
SP-17 (Lea et al, 1998), SP-10 (Herr et al, 1990), FA-1
(Zhu and Naz, 1997), and YLP12 (Naz et al, 2000). Most
of these active immunization studies, except those related
to the PH-20 antigen, were carried out in the mouse mod-
el. At the present time, no sperm antigen has undergone
a phaseI/II clinical trial in humans. Two studies have ex-
amined the effect of sperm antigen vaccination in a non-
human primate model. One study reported reduced fertil-
ity of female baboons after immunization with LDH-C4
(O’Hearn et al, 1997). However, a study by another group
found no effect on fertility in female monkeys after vac-
cination with LDH-C4 (Tollner et al, 2002). The reason
for this discrepancy is not clear. Recently, in an interest-
ing study, male monkeys were immunized with an epi-
didymal protein designated as epididymal protein inhibi-
tor (Eppin; O’Rand et al, 2004). After immunization, 78%
of monkeys who developed high anti-Eppin antibody ti-
ters became infertile, and 71% of those monkeys recov-
ered fertility after immunization was stopped. To maintain
high antibody titers, booster injections with Freund’s ad-
juvant have to be administered every 3 weeks for almost
the entire duration of the study, 691 days. The potential
immunopathological effects of immunization were not ex-
amined. This interesting study indicates that anti-sperm
CV can also be developed for men.
Antibodies to several sperm molecules inhibit sperm-
oocyte interaction/fertilization in vitro. However, the ac-
tive immunization with many of these molecules does not
inhibit fertility in vivo. In addition, the gene knockouts
of many of these molecules do not inhibit fertility. For
example, although antibodies to fertilin/PH-30 inhibit fer-
tilization in vitro (Stein et al, 2004), active immunization
with fertilin/PH-30 does not affect fertility in vivo (Hardy
et al, 1997). Similarly, although antibodies to sperm in-
tegrins a6 and b1 inhibit sperm-oocyte fusion in vitro (Al-
meida et al, 1995), the gene knockouts of these molecules
do not affect the fertility in vivo (He et al, 2003). These
differences in in vitro and in vivo effects may be a result
of 1) the class/subclass, valency, affinity, and kinetics of
the antibodies generated in vivo; 2) the fact that antibod-
ies have to be present in time and space to bind to the
appropriate molecules; and/or 3) a possible redundancy
of some of these molecules.
Another problem that the sperm vaccinologists are cur-
rently facing is finding an appropriate animal model to
examine the efficacy of a sperm antigen. The most used
animal model is the mouse. However, until now, no one
has reported a 100% block in fertility after immunization
with any single antigen in the mouse model. Even im-
munization with the whole sperm or their solubilized
preparations does not cause a total block in fertility in
mice, male or female. The maximum reduction in fertility
after immunization with any antigen/sperm preparation is
up to 70% to 75%. Very few, if any, knockouts of a single
gene have made mice totally infertile. The recently re-
ported Izumo gene knockout did make the male mice al-
most totally infertile (Inoue et al, 2005). It remains to be
seen whether the 70% to 75% reduction in fertility in the
mouse model translates to a 100% reduction in humans.
The female mouse ovulates several (approximately 20–
50) eggs every cycle and a woman ovulates mostly 1 egg
every cycle. Therefore, there are differences between the
mouse and human. It is possible that a 70% to 75% re-
duction in fertility in the mouse model translates to a
100% block in humans. It is possible that it is an inherent
nature of the mouse model that it is difficult to make mice
completely infertile. However, after active immunization
or deleting a single gene, one does find a few mice that
are totally infertile. There is no study at the present time
that has examined the effect of immunization with more
than 1 sperm antigen in the mouse model.
The phage display technology is a novel and innovative
tool for delineating specific binding peptide sequences to
various ligands and antibodies. It was first reported by
George Smith in 1985 (Smith, 1985). This technology is
currently being widely used in several laboratories. The
peptide sequences are presented on the surface of fila-
mentous phage to examine their interaction with specific
ligands/antibodies. The DNA encoding any peptide se-
quence is incorporated into the genome of the phage cap-
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sid protein, and the encoded peptide is expressed and dis-
played on the phage surface as a fusion protein. Recently,
we used this technology to delineate the peptide sequenc-
es that are involved in human immunoinfertility, and the
peptide sequences present on human sperm cells that are
involved in binding to human ZP.
Using the antibody-positive sera from immunoinfertile
men, seven clones that had dodecamer sequences in a
random order, designated #2, #22, #69, #77, #81, #84,
and #95, were identified in the phage display library (Naz,
2005b). These clones did not react with the antibody-
negative sera from fertile men. The clones were se-
quenced (#2, PSALGRFTRGPL; #22, SLIFVTISSEWG;
#69, LSLSLDLLTFRT; #77, PDIRHYFIQNRG; #81,
GCRIVYRRPLHL; #84, RTAGFDIKLIDT; and #95,
RIQYQAISTVSL) and the peptides were synthesized
based on these 7 sequences and investigated for their im-
munoreactivity with sera from immunoinfertile and fertile
men in the enzyme-linked immunosorbent assay. All of
the 7 peptides, and especially 3 peptides (#22, #69, and
#95), reacted strongly with the immunoinfertile sera,
compared with the fertile sera. These 3 peptides reacted
with 27% to 40% of the immunoinfertile sera for the IgG
class, and two of these (#69 and #95) also showed a pos-
itive reaction with 27% of the sera for the IgA class. None
of the peptides reacted positively with the fertile sera.
These peptide sequences are novel, without any complete
identity with any known sequence in the database. The
sperm cell has several proteins on the surface, some are
glycosylated. Many of these peptides may constitute par-
tial or complete peptide mimetics of the carbohydrate epi-
topes present on sperm that are involved in immunoin-
fertility. The phage display technology seems to be a
powerful tool to identify immunoinfertility-associated
sperm antigens, both the peptide moieties as well as the
carbohydrate mimetics of the peptide epitopes. In the past,
several proteomic methodologies, immunologic tech-
niques, and the two-dimensional gel electrophoresis/ma-
trix-assisted laser desorption mass spectrometry have
been used to delineate molecular identities of the sperm
antigens that are involved in antisperm antibody-mediated
immunoinfertility (Auer et al, 1995; Pillai et al, 1996;
Shetty et al, 1999). Although a few interesting leads have
been found, very few sperm antigens have been identified
that are indeed involved in immunoinfertility. The FA-1
antigen was identified in our laboratory, and the comple-
mentary DNA (cDNA) encoding for the FA-1 antigen has
been cloned and sequenced from the mouse (Zhu and
Naz, 1997) and human testis (Naz and Zhu, 2002). The
FA-1 antigen has been clearly shown to be associated
with immunoinfertility (Naz et al, 1993). Antibodies to
the FA-1 antigen are present in sperm, seminal plasma,
and sera of immunoinfertile men, and in follicular fluid,
cervical mucus, vaginal secretions, and sera of women.
A clinical trial conducted at the University of Michigan
Medical School indicates that the incubation of sperm
from immunoinfertile men with the FA-1 antigen removes
autoantibodies from the sperm surface, resulting in an in-
crease in the antibody-free sperm, and enhanced acrosome
reaction rates (Menge et al, 1999). The intrauterine in-
semination of FA-1 antigen-adsorbed antibody-free sperm
caused normal pregnancies and healthy babies, indicating
that the antigen treatment does not have deleterious ef-
fects on implantation or on embryonic and fetal devel-
opment. Thus, the FA-1 antigen, along with other sperm
antigens that are involved in immunoinfertility, may find
application in immunotherapy of immunoinfertility, be-
sides having application in the specific diagnosis.
Using the solubilized preparation of human ZP as a
probe, a dodecamer sequence (YLPVGGLRRIGG), des-
ignated as YLP12, present on human sperm, was identified
using the phage display library (Naz et al, 2000a). An
extensive computer search in the database did not reveal
any known sequence with a complete identity or signifi-
cant homology with YLP12. Antibodies to synthetic YLP12
peptide inhibit human sperm-human zona binding. YLP12
recognizes the ZP3 component of human ZP. The YLP12
peptide sequence was localized primarily on the acrosome
and tail regions of humans and murine sperm (Naz et al,
2000). This peptide is also involved in human immunoin-
fertility. To examine the immunocontraceptive potential,
a vaccine was prepared by conjugating the YLP12 peptide
with the recombinant cholera toxin B subunit (rCTB; Naz
and Chauhan, 2002). The YLP12 peptide-rCTB vaccine
caused a significant inhibition of infertility (up to 71%)
in vaccinated female mice by raising a testis/sperm-spe-
cific immune response. The fertility reversed after ap-
proximately 10 months, when the antibodies disappeared
from the circulation and genital tract. The fertility could
also be reversed voluntarily at any given time by neu-
tralizing the antibodies, which is done by administering
the unconjugated peptide in the blood and/or in the va-
gina.
Besides antibodies, various cytokines can also affect
sperm function and fertility, positively or negatively. For
example, interferon-g and tumor necrosis factor-a can
negatively affect sperm motility and function (Naz and
Kumar, 1991), and interleukin-6 can enhance sperm ca-
pacitation and acrosome reaction (Naz and Kaplan, 1994).
Spermatozoa have receptors for many of these cytokines,
such as interferon-g and interferon-a (Naz et al, 2000b).
These factors are present in the seminal plasma, and the
levels are modulated to various degrees in infertility. Im-
munization with whole-sperm preparations or specific
sperm antigens can raise many cytokines in addition to
antibodies that can affect sperm function (Naz and Mehta,
1989). DNA vaccines have been extensively used to gen-
erate protective immunity against infectious agents and
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tumors (Liu, 2003; Patil et al, 2005). DNA vaccination
represents one of the recent advancements in vaccine
technology. DNA vaccines have distinct advantages over
the peptide vaccines because they have potential to gen-
erate both T helper cell subsets 1 and 2 immune respons-
es. Based on these facts, a DNA vaccine was prepared by
cloning YLP12 cDNA into a pVAX1 DNA vector. The
female mice were immunized intraderminally with the
YLP12 DNA vaccine via a gene gun. The DNA vaccina-
tion caused a long-term contraception in female mice (un-
published data).
The progress in the development of CVs against vari-
ous targets, including sperm, has been hampered by the
following factors: 1) difficulty in delineating the appro-
priate fertility-related antigen(s), 2) variability of the im-
mune response among the vaccinated individuals, 3) at-
tainment and maintenance of high titers of antibodies for
bioefficacy, 4) time lag to achieve reasonably good anti-
body titers after the first injection, and 5) uncertainty re-
garding how long the antibody titer will remain in the
circulation to exercise the contraceptive effects. The last
4 concerns are associated with the active immunization
studies involving CVs. It is envisaged that these 4 con-
cerns may be taken care of using the passive immuniza-
tion approach (Naz and Rajesh, 2004). The passive im-
munization approach has been successful for protection
against various immunologic and infectious diseases
(Casadevall, 1999; Zeitlin et al, 2000). These studies have
indicated that administration of homologous antibody
preparations, especially the Fabs, are devoid of any side
effect and immunopathological consequences. The bioef-
ficacy of the passive immunization depends on the class/
subclass of immunoglobulins and the route of antibody
administration. Human IgG has a half-life of 21 days.
Recently, there has been a growing interest to humanize
the murine monoclonal antibodies or to raise human
monoclonal antibodies against various sperm contracep-
tive epitopes (Isojima et al, 1987; Clayton et al, 1998;
Norton et al, 2001). These antibodies, and additional an-
tibodies that are being engineered, await trials in animal
models and in humans for demonstration of efficacy, du-
ration, and reversibility of the antifertility effects. The
data from antibody therapies, including clinical trials in
infectious diseases, indicate that it is an exciting, practi-
cal, viable, and durable proposition ready for experimen-
tation.
In conclusion, a CV targeting sperm is an exciting
proposition. The strong rationale and the progress made
during the last several years indicate that it can culminate
in a viable and successful reality. The immunologic ap-
proaches to contraception have been a priority of the
World Health Organization since 1973, and were highly
recommended by the Institute of Medicine in its 1996
report.
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